Design Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 66.86 million compared to USD 63.31 million a year ago. Basic loss per share from continuing operations was USD 1.19 compared to USD 1.14 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.06 USD | -0.25% | -3.56% | +53.21% |
May. 08 | Design Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 07 | Piper Sandler Upgrades Design Therapeutics to Overweight From Neutral | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+53.21% | 230M | |
+46.19% | 56.65B | |
-6.14% | 39.44B | |
+39.19% | 39.03B | |
-6.65% | 26.86B | |
+12.33% | 26.75B | |
-21.78% | 19.03B | |
-0.35% | 12.28B | |
+24.18% | 12.26B | |
+28.38% | 12.04B |
- Stock Market
- Equities
- DSGN Stock
- News Design Therapeutics, Inc.
- Design Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023